Verasonics sues SuperSonic Imagine
Research ultrasound technology developer Verasonics has filed a patent infringement...Read more on AuntMinnie.comRelated Reading: SuperSonic to feature Aixplorer Ultimate at ECR FDA clears SuperSonic's Aixplorer for liver disease Verasonics buries hatchet with Alpinion U.S. court confirms Verasonics arbitration award Verasonics claims arbitration win against Alpinion
CONCLUSION: Patients with non-alcoholic fatty liver disease showed elevated levels of circulating Hb, evidence that suggests that Hb exerts a protective role, as it may act as an antioxidant and may counteract the adverse effects of this disease. PMID: 29893698 [PubMed - in process]
This study investigated risk factors for nonsurveillance and advanced HCC at diagnosis and their effect on survival. Materials and Methods: Two hundred seventy HCC patients were included. Clinical data were collected from hospital databases. Results: One hundred twenty-eight (47.1%) patients had 6-monthly ultrasound surveillance before HCC diagnosis. Ninety-two (34.1%) patients had advanced HCC (multifocal or total diameter ≥6 cm) at diagnosis. The nonsurveillance rate was significantly higher in nonalcoholic fatty liver disease (NAFLD) (79%) compared with other causes of chronic liver disease (31.6% to 58.1%, P
Authors: Tana C, Schiavone C, Ticinesi A, Lauretani F, Nouvenne A, Dietrich CF, Meschi T Abstract Ultrasound (US) can reveal the presence of steatosis in non-alcoholic fatty liver disease (NAFLD), but its diagnostic accuracy to reveal signs of fibrosis is low except in advanced stages of disease (e.g. cirrhosis). Current guidelines suggest the use of clinical algorithms, such as the NAFLD fibrosis score, and elastography to predict the progression of fibrosis, and the integration of elastography improves the detection accuracy of liver stiffness. However, there is a lack of evidence about the correlation between cl...
This article reviews the indication of EUS in the evaluation and treatment of portal hypertension, portal vein pressure measurement, focal liver lesions, and parenchymal liver diseases, and presents all the clinical evidences available so far in this regard. All the review data suggest that EUS is becoming an increasingly important tool in the armamentarium of the hepatologists for the management of certain liver-related conditions. Implementation in the education of the hepatologists of means to become more familiar with both diagnostic and therapeutic capabilities of EUS is warranted. [...] Thieme Medical Publishers 333 ...
Semin Liver Dis 2018; 38: 160-169 DOI: 10.1055/s-0038-1655775The diagnosis of malignant biliary strictures remains problematic, especially in the perihilar region and in primary sclerosing cholangitis (PSC). Conventional cytology obtained during endoscopic retrograde cholangiography (ERC)-guided brushings of biliary strictures is suboptimal due to limited sensitivity, albeit it remains the gold standard with a high specificity. Emerging technologies are being developed and validated to address this pressing unmet patient need. Such technologies include enhanced visualization of the biliary tree by cholangioscopy, intraduct...
CONCLUSIONS: Our study provides evidence of a high prevalence of epidemiological changes in HCV infection with a major prevalence of advanced liver disease, such as portal hypertension, in this elderly cohort of patients. PMID: 29847179 [PubMed - as supplied by publisher]
Conclusions: NAFLD is a very common disease in obese children. NAFLD predictive risk factors include increased waist circumference, elevated WHR and WHtR, and elevated total cholesterol, triglycerides, and fasting insulin as well as elevated glucose and insulin concentration in the OGTT and HOMA-IR index. NAFLD increases the risk of potential cardiovascular complications expressed by diagnosis of metabolic syndrome. The best independent predictive risk factor for diagnosing NAFLD in obese children is fasting insulin> 18.9 uIU/ml. PMID: 29854716 [PubMed - in process]
Although liver liver biopsy can be performed by percutaneous, transjugular, and surgical routes, Endoscopic Ultrasound (EUS) is a rapidly evolving technology that is now used for liver biopsies, especially in patients in who percutaneous biopsy is technically difficult. EUS guided liver biopsy (EUSLB) has the theoretical advantage of being more safe as it is not a ‘blind biopsy’ and provides a superior method for screening for initial screening of portal hypertension and esophageal varices. Several studies have shown that EUSLB is feasible and safe.
ecent studied have showed that EUS- guided liver biopsy(EUS-LB) using FNB needle is feasible, safe and has several advantages over percutaneous liver biopsy(PC-LB) including improved tissue acquisition ( more specimen length and complete portal tracts). It is not only safer and but also targets areas and focal lesions in both lobes, may substitute ultrasound based screening for HCC and simultaneously provide a superior method for initial screening of portal hypertension and esophageal varices. However, to be clinically viable in Hepatology practice, such an approach needs to be cost-effective.
The yield of endoscopic ultrasound (EUS)-guided liver biopsy (LB) in parenchymal disease evaluation has been previously studied, although with large-gauge needles and in retrospective or ex-vivo studies. In a prospective study, we evaluated the feasibility, safety and diagnostic adequacy of EUS-LB using a small caliber, 22-gauge (22-G) needle, in patients with nonalcoholic fatty liver disease (NAFLD) and suspected early-stage fibrosis. A validated histopathologic NAFLD scale served as a benchmark to evaluate adequacy of acquired tissue.